Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma(Kmm150).
Jung SH et al. Biol Blood Marrow Transplant. 2018 Jan 12. pii: S1083-8791(18)30019-3. doi: 10.1016/j.bbmt.2018.01.004. [Epub ahead of print].
The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
Comeau JM et al. Am J Health Syst Pharm. 2018 Jan 15;75(2):55-66. doi: 10.2146/ajhp160554.
An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma.
Lee L et al. Blood. 2017 Dec 28. pii: blood-2017-05-781351. doi: 10.1182/blood-2017-05-781351. [Epub ahead of print].
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Richardson PG et al. Future Oncol. 2017 Dec 22. doi: 10.2217/fon-2017-0616. [Epub ahead of print].